Siroos Mirzaei

Siroos Mirzaei
Born (1963-04-22) April 22, 1963
Mashhad, Iran
Scientific career
FieldsTorture diagnostics, Dementia diagnostics, thyroid diseases, neuroendocrine diseases (NET)
WorkplacesWilhelminen Hospital in Vienna

Siroos Mirzaei (born 22 April 1963 in Mashhad)[a] is an Iranian specialist in Nuclear Medicine. He is Head of the Department of Nuclear Medicine of the Wilhelminen Hospital in Vienna.[1] Mirzaei is well known for his scientific work on torture diagnostics with molecular imaging methods.

Biography

Mirzaei spent his childhood and adolescence in Mashhad, Iran. When he was 18 years old, he moved to Austria to study medicine at the University of Vienna.[2] He graduated in 1987 and after some experimental jobs such as at the Department of Experimental Anesthesiology of the Vienna General Hospital he moved, in 1989, to Luxembourg to continue his postdoctoral education at the Department of Cardiology and the Department of Infectious Diseases of the Centre Hospitalier de Luxembourg. In 1994 he completed his specialist training in Family Medicine at the Kaiserin Elisabeth Hospital in Vienna and received the Board Certification in General Medicine. In 1994, he changed to Wilhelminen Hospital in Vienna to complete his specialist medical training in Nuclear Medicine which he was certified for in 1998. In the same year, Mirzaei went to Heidelberg, Germany for a research sabbatical at the Department of Endocrinology of the Ruprecht-Karls-University and afterwards he started to work as Staff Physician at the Wilhelminen Hospital Vienna. In 2004, Mirzaei was appointed professor for Nuclear Medicine at the University of Vienna. Since 2007, he has been Head of the Department of Nuclear Medicine at the Wilhelminen Hospital Vienna.[1] Professor Siroos Mirzaei is actively committed to establishing democracy in Iran. He is also a member of the 7 Aban Front, a political movement opposing the Islamic regime in Iran.[3]

Scientific contribution

Mirzaei has been contributing to the following fields of research:

Honors and awards

  • 1996: Elscint Programmier Förderungspreis for the project "Iterative reconstruction of SPECT-Data on an Elscint-Workstation"
  • 1999: Mallinckrodt Förderungspreis Nuklearmedizin for the study "Bone Scintigraphy in Screening of Torture Survivors" published in The Lancet[34]
  • 2000: Solidarity Prize of the archdiocese Vienna for the influence of his work on Integration (Hemayat)
  • In 2008, Mirzaei himself has introduced a prize called "Young Human Rights Activist Award 2008", which was won by a team from India for its innovative concept on human rights.[35]

Memberships in organisations

Mirzaei's research activity is connected with memberships in various organisations.[2] He was for more than ten years head of the Education Working Group as well as board member of the Austrian Society of Nuclear Medicine, president of the Austrian Nuclear Medicine Physician Union and member of the executive committee of the European Board of Nuclear Medicine (UEMS).[36] He also contributes his expertise to the Austrian Society for Radiation Protection, the Society of Nuclear Medicine (SNM), USA and the organisation Doctors without Borders. He is spokesman of the medical division of Amnesty International Austria, expert in the field of torture diagnostics in the Istanbul Protocol[37] and founding member of the organisation HEMAYAT.[38]

Mirzaei is also a member of the editorial board of the following scientific journals: Asia Oceania Journal of Nuclear Medicine & Biology,[39] Iranian Journal of Nuclear Medicine[40] and BMC International Health & Human Rights.

Publications

Mirzaei has published over 100 articles in scientific journals.[41]

He is also author of the following two books:

  • Mirzaei, Siroos; Irdische Träume im Paradies: Roman. Innsbruck: Tiroler Autorinnen u. Autoren Koop., 2012. ISBN 978-3-900888-53-4
  • Mirzaei, Siroos; Schenk, Martin: Images of Torture. Heyamat: 15 Years of Work with Traumatised Refugees. Wien: Mandelbaum Verlag, 2010. ISBN 978385476-351-2[42]

Notes

  1. ↑ Persian: سیروس میرزایی

References

  1. 1 2 Department of Nuclear Medicine, Wilhelminen Vienna
  2. 1 2 CV Mirzaei Siroos
  3. ↑ "The Speech of Professor Sirous Mirzaei at the 7 Aban Front Conference". 7aban.org.
  4. ↑ Zandieh, S; Bernt, R; Knoll, P; Wenzel, T; Hittmair, K; Haller, J; Hergan, K; Mirzaei, S (Apr 2016). "Analysis of the Metabolic and Structural Brain Changes in Patients With Torture-Related Post-Traumatic Stress Disorder (TR-PTSD) Using 18F-FDG PET and MRI". Medicine (Baltimore). 95 (15) e3387. doi:10.1097/MD.0000000000003387. PMC 4839854. PMID 27082610.
  5. ↑ Wenzel, T; Frewer, A; Mirzaei, S (2015). "The DSM 5 and the Istanbul Protocol: Diagnosis of psychological sequels of torture". Torture. 25 (1): 51–61. PMID 26021347.
  6. ↑ Mirzaei, S; Sonneck-Koenne, C; Bruecke, T; Aryana, K; Knoll, P; Zakavi, R (2012). "Supplementary value of functional imaging in forensic medicine". Torture. 22 Suppl 1: 14–20. PMID 22948398.
  7. ↑ Mirzaei, S; Knoll, P; Köhn, H (2004). "[Medical aspects of objectifying torture sequels]". Wien Klin Wochenschr. 116 (15–16): 568–74. doi:10.1007/BF03217712. PMID 15471186.
  8. ↑ Mirzaei, S; Knoll, P; Keck, A; Preitler, B; Gutierrez, E; Umek, H; Köhn, H; Pecherstorfer, M (2001). "Regional cerebral blood flow in patients suffering from post-traumatic stress disorder". Neuropsychobiology. 43 (4): 260–4. doi:10.1159/000054900. PMID 11340366.
  9. ↑ Wenzel, T; Griengl, H; Stompe, T; Mirzaei, S; Kieffer, W (2000). "Psychological disorders in survivors of torture: exhaustion, impairment and depression". Psychopathology. 33 (6): 292–6. doi:10.1159/000029160. PMID 11060511.
  10. ↑ Mirzaei, S; Knoll, P; Lipp, RW; Wenzel, T; Koriska, K; Köhn, H (1998). "Bone scintigraphy in screening of torture survivors". Lancet. 352 (9132): 949–51. doi:10.1016/s0140-6736(98)05049-1. PMID 9752817.
  11. ↑ Capasso, E; Durzu, S; Piras, S; Zandieh, S; Knoll, P; Haug, A; Hacker, M; Meleddu, C; Mirzaei, S (Jul 2015). "Role of (64)CuCl 2 PET/CT in staging of prostate cancer". Ann Nucl Med. 29 (6): 482–8. doi:10.1007/s12149-015-0968-4. PMID 25833290.
  12. 1 2 Zandieh, S; Pokieser, W; Knoll, P; Sonneck-Koenne, C; Kudlacek, M; Mirzaei, S (Jun 2015). "Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan". Acta Radiol. 56 (6): 709–13. doi:10.1177/0284185114537928. PMID 24948789.
  13. ↑ Ahmadzadehfar, H; Rodrigues, M; Zakavi, R; Knoll, P; Mirzaei, S (Dec 2011). "Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma". Med Oncol. 28 (4): 1570–6. doi:10.1007/s12032-010-9584-2. PMID 20524086.
  14. ↑ Prosch, H; Mirzaei, S; Oschatz, E; Strasser, G; Huber, M; Mostbeck, G (2005). "Case report: Gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer". Br J Radiol. 78 (932): 758–61. doi:10.1259/bjr/55106848. PMID 16046432.
  15. ↑ Fink, AM; Holle-Robatsch, S; Herzog, N; Mirzaei, S; Rappersberger, K; Lilgenau, N; Jurecka, W; Steiner, A (2004). "Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II". Melanoma Res. 14 (2): 141–5. doi:10.1097/00008390-200404000-00011. PMID 15057045.
  16. ↑ Mirzaei, S; Guerchaft, M; Bonnier, C; Knoll, P; Doat, M; Braeutigam, P (2005). "Use of segmented CT transmission map to avoid metal artifacts in PET images by a PET-CT device". BMC Nucl Med. 5 (1) 3. doi:10.1186/1471-2385-5-3. PMC 1164418. PMID 15953395.
  17. ↑ Mirzaei, S; Schratter-Sehn, AU; Knoll, P; Gerber, E; Kumpan, W; Schiessel, R; Raderer, M; Köhn, H (2001). "[Determination of therapy management in rectal carcinoma by staging with 18-FDG-PET]". Chirurg. 72 (9): 1058–61. doi:10.1007/s001040170075. PMID 11594277.
  18. ↑ Mirzaei, S; Knoll, P; Kohn, H (2001). "Diagnosis of recurrent astrocytoma with fludeoxyglucose F18 PET scanning". N Engl J Med. 344 (26): 2030–1. doi:10.1056/NEJM200106283442614. PMID 11430342.
  19. ↑ Dimou, E; Booij, J; Rodrigues, M; Prosch, H; Attems, J; Knoll, P; Zajicek, B; Dudczak, R; Mostbeck, G; Kuntner, C; Langer, O; Bruecke, T; Mirzaei, S (2009). "Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment". Curr Alzheimer Res. 6 (3): 312–9. doi:10.2174/156720509788486563. PMID 19519314.
  20. ↑ Mirzaei, S; Gelpi, E; Booij, J; Rodrigues, M; Neumann, I; Zaknun, J; Koehn, H; Knoll, P (2004). "New approaches in nuclear medicine for early diagnosis of Alzheimer's disease". Curr Alzheimer Res. 1 (3): 219–29. doi:10.2174/1567205043332135. PMID 15975069.
  21. ↑ Mirzaei, S; Rodrigues, M; Koehn, H; Knoll, P; Bruecke, T (2003). "Metabolic impairment of brain metabolism in patients with Lewy body dementia". Eur J Neurol. 10 (5): 573–5. doi:10.1046/j.1468-1331.2003.00650.x. PMID 12940841.
  22. ↑ Mirzaei, S; Knoll, P; Koehn, H; Bruecke, T (2003). "Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET)". BMC Nucl Med. 3 (1): 1. doi:10.1186/1471-2385-3-1. PMC 151666. PMID 12625839.
  23. ↑ B Grubmüller, R P Baum, E Capasso, A Singh, Y Ahmadi, P Knoll, A Floth, S Righi, S Zandieh, C Meleddu, S F Shariat, H C Klingler, S Mirzaei (2016) 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies Cancer Biotherapy and Radiopharmaceuticals.
  24. ↑ Mirzaei, S; Bastati, B; Lipp, RW; Knoll, P; Zojer, N; Ludwig, H (2011). "Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors". Oncology. 80 (5–6): 326–9. doi:10.1159/000329808. PMID 21791941.
  25. ↑ Rosenberger, I; Strauss, A; Dobiasch, S; Weis, C; Szanyi, S; Gil-Iceta, L; Alonso, E; González Esparza, M; Gómez-Vallejo, V; Szczupak, B; Plaza-García, S; Mirzaei, S; Israel, LL; Bianchessi, S; Scanziani, E; Lellouche, JP; Knoll, P; Werner, J; Felix, K; Grenacher, L; Reese, T; Kreuter, J; Jiménez-González, M (Sep 2015). "Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer". J Control Release. 214: 76–84. doi:10.1016/j.jconrel.2015.07.017. hdl:2434/503522. PMID 26192099.
  26. ↑ Popov V, Gospavic R, Knoll P, Mirzaei S. "Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours. Asia Oceania Journal of Nuclear Medicine & Biology 2016.
  27. ↑ Ahmadihosseini, H; Abedi, J; Ghodsi Rad, MA; Zakavi, SR; Knoll, P; Mirzaei, S; Sadeghi, R (Dec 2014). "Diagnostic utility of 99mTc-EDDA-tricine-HYNIC-Tyr3-octreotate SPECT for differentiation of active from inactive pulmonary tuberculosis". Nucl Med Commun. 35 (12): 1262–7. doi:10.1097/MNM.0000000000000206. PMID 25222910.
  28. ↑ Mirzaei, S; Sohlberg, A; Knoll, P; Zakavi, R; Diemling, M (Sep 2013). "Easy-to-use online software package for internal dose assessment after radionuclide treatment in clinical routine". Clin Nucl Med. 38 (9): 686–90. doi:10.1097/RLU.0b013e31828da3db. PMID 23640224.
  29. ↑ Neumann, I; Mirzaei, S; Birck, R; Osinger, K; Waldherr, R; Köhn, HD; Meisl, FT (Feb 2004). "Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis". Rheumatology (Oxford). 43 (2): 195–201. doi:10.1093/rheumatology/keg479. PMID 12949255.
  30. ↑ Zandieh, S; Bernt, R; Zwerina, J; Haller, J; Knoll, P; Seyeddain, O; Mirzaei, S (Mar 2016). "Acoustic Structure Quantification Analysis of the Thyroid in Patients with Diffuse Autoimmune Thyroid Disease". Ultrason Imaging. 38 (2): 137–47. doi:10.1177/0161734615580766. PMID 25855160.
  31. ↑ Schnedl, WJ; Mirzaei, S; Wallner-Liebmann, SJ; Tafeit, E; Mangge, H; Krause, R; Lipp, RW (Jun 2013). "Improvement of Cerebral Hypoperfusion with Levothyroxine Therapy in Hashimoto's Encephalopathy Demonstrated by (99m)Tc-HMPAO-SPECT". Eur Thyroid J. 2 (2): 116–9. doi:10.1159/000348523. PMC 3821506. PMID 24783049.
  32. ↑ Pestitschek, M; Sonneck-Koenne, C; Zakavi, SR; Li, S; Knoll, P; Mirzaei, S (Mar 2013). "Selenium intake and selenium blood levels: a novel food frequency questionnaire". Wien Klin Wochenschr. 125 (5–6): 160–4. doi:10.1007/s00508-013-0334-2. PMID 23508871.
  33. ↑ Mirzaei, S; Krotla, G; Knoll, P; Koriska, K; Köhn, H (1999). "Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy". Acta Med Austriaca. 26 (1): 29–31. PMID 10230474.
  34. ↑ Mirzaei, S; Knoll, P; Lipp, Rw; Wenzel, Th; Koriska, K; Köhn, H (1998). "Bone Scintigraphy in Screening of Torture Survivors". The Lancet. 352 (9132): 949–51. doi:10.1016/S0140-6736(98)05049-1. PMID 9752817.
  35. ↑ Young Human Rights Activist Award 2008, nominations and winner
  36. ↑ European Association of Nuclear Medicine (EBDN), Executive Committee
  37. ↑ Istanbul Protocol, list of experts
  38. ↑ HEMAYAT.org
  39. ↑ Asia Oceania Journal of Nuclear Medicine & Biology, Editorial Board Members
  40. ↑ Iranian Journal of Nuclear Medicine, Editorial Board Members
  41. ↑ "List of Publications, Research Gate". Research Gate. Retrieved 2016-9-24
  42. ↑ Images of Torture, Mandelbaum publisher
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.